caa a22 4500 606236120 CHVBK 20210128101246.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s11010-015-2424-0 doi (NATIONALLICENCE)springer-10.1007/s11010-015-2424-0 Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro [Elektronische Daten] [Weidong Li, Shakir Saud, Matthew Young, Nancy Colburn, Baojin Hua] Cryptotanshinone (CPT) is a natural compound extracted from herbal medicine that has been previously shown to possess antitumor properties in various types of human cancer cells. In the present study, we examined the potential role of CPT in the treatment of colorectal cancer. Using SW480, HCT116, and LOVO colorectal cancer cell lines, the effects of CPT on cell viability, apoptosis, and tumorigenicity were evaluated. The results showed that CPT significantly inhibited the growth and viability of SW480, HCT116, and LOVO cell lines by inducing apoptosis and prevented anchorage dependent growth on agar. In addition, CPT inhibited the activation of Signal transducer and activator of transcription 3 (Stat3) pathways in colorectal cancer cells. Stat3 is a transcription factor that mediates the expression of various genes associated with many cellular processes, such as inflammation and cell growth, and has been shown to promote several cancer types, including colorectal cancer. These findings indicate that CPT may be a potential candidate for the treatment and prevention of colorectal cancer in part by inhibiting the activation of Stat3. Springer Science+Business Media New York, 2015 Cryptotanshinone nationallicence Colorectal cancer treatment nationallicence Signal transducer and activator of transcription 3 nationallicence Proliferation nationallicence Apoptosis nationallicence Li Weidong Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053, Beijing, China aut Saud Shakir Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 20850, Rockville, MD, USA aut Young Matthew Basic Research Laboratory, Center for Cancer Research, Frederick National Laboratory of Cancer Research, 21702, Frederick, MD, USA aut Colburn Nancy Basic Research Laboratory, Center for Cancer Research, Frederick National Laboratory of Cancer Research, 21702, Frederick, MD, USA aut Hua Baojin Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053, Beijing, China aut Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 406/1-2(2015-08-01), 63-73 0300-8177 406:1-2<63 2015 406 11010 https://doi.org/10.1007/s11010-015-2424-0 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s11010-015-2424-0 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Li Weidong Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053, Beijing, China aut NATIONALLICENCE 700 1- Saud Shakir Nutritional Science Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 20850, Rockville, MD, USA aut NATIONALLICENCE 700 1- Young Matthew Basic Research Laboratory, Center for Cancer Research, Frederick National Laboratory of Cancer Research, 21702, Frederick, MD, USA aut NATIONALLICENCE 700 1- Colburn Nancy Basic Research Laboratory, Center for Cancer Research, Frederick National Laboratory of Cancer Research, 21702, Frederick, MD, USA aut NATIONALLICENCE 700 1- Hua Baojin Oncology Department, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, 100053, Beijing, China aut NATIONALLICENCE 773 0- Molecular and Cellular Biochemistry Springer US; http://www.springer-ny.com 406/1-2(2015-08-01), 63-73 0300-8177 406:1-2<63 2015 406 11010